Executive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Eli Lilly and Company
LLY
Current price
$660.49
Eli Lilly leads the GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, generating billions in revenue despite recent clinical trial setba...
Eli Lilly leads the GLP-1 market with blockbuster drugs like Mounjaro and Zepbound, generating billions in revenue despite recent clinical trial setbacks.
Novo Nordisk A/S
NVO
Current price
$50.90
Novo Nordisk pioneered the GLP-1 space with Ozempic and Wegovy, maintaining a strong competitive position in the rapidly growing obesity treatment mar...
Novo Nordisk pioneered the GLP-1 space with Ozempic and Wegovy, maintaining a strong competitive position in the rapidly growing obesity treatment market.
Altimmune Inc
ALT
Current price
$4.74
Altimmune develops next-generation obesity treatments including pemvidutide, positioning itself as a potential challenger in the competitive GLP-1 lan...
Altimmune develops next-generation obesity treatments including pemvidutide, positioning itself as a potential challenger in the competitive GLP-1 landscape.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
When company executives buy shares after a stock drop, it often signals deep confidence in their business. Following Eli Lilly's clinical trial setback, top executives including the CEO invested millions in company shares, suggesting they believe the market overreacted to short-term news whilst the long-term GLP-1 opportunity remains strong.
What You Need to Know
This group focuses on the rapidly expanding obesity treatment sector, dominated by GLP-1 drugs but also including next-generation therapies and novel delivery systems. The market is highly competitive and can be volatile, but represents one of healthcare's fastest-growing segments with enormous potential as obesity rates continue rising globally.
Why These Stocks
These companies were handpicked to capture the full spectrum of the weight-loss drug market. From established leaders like Eli Lilly and Novo Nordisk to innovative challengers developing breakthrough therapies, this collection provides exposure to both proven players and emerging opportunities in this dynamic healthcare segment.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+703.81%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 703.81% over the next year.
Stocks Rated Buy by Analysts
14 of 15 assets in this group are rated Buy by professional analysts.
Why You'll Want to Watch These Stocks
Following the Smart Money
When executives buy shares after bad news, they're betting their own money on recovery. This insider confidence often signals opportunities that the broader market has missed.
Massive Market Potential
The global obesity treatment market is exploding, with GLP-1 drugs already generating tens of billions in revenue and still in early adoption phases worldwide.
Innovation Pipeline Heating Up
Beyond established players, numerous companies are developing next-generation therapies, novel delivery methods, and breakthrough approaches that could reshape this entire sector.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AI's App Store Showdown
Elon Musk's threat of an antitrust lawsuit against Apple highlights the growing tension between AI developers and the powerful app store gatekeepers. This situation could create opportunities for other technology companies that offer alternative platforms or help developers navigate the competitive app landscape.
Navigating The Fed's Inflation Dilemma
A recent spike in inflation, driven by import tariffs, has put the Federal Reserve in a difficult position. This theme focuses on companies that could benefit from this economic tension, whether through competitive pricing or a potential interest rate cut.
Grounded Giant: Rivals Poised To Gain From Air Canada Strike
A potential strike at Air Canada threatens to ground the nation's largest airline, creating significant travel disruption. This presents a tactical opportunity for rival airlines to capture market share and benefit from the surge in demand from displaced travelers.
Frequently Asked Questions
Everything you need to know about the product and billing.